Karyopharm Therapeutics Inc

This study is testing whether adding a new drug called selinexor to standard chemotherapy (R-GDP) works better for people with relapsed or resistant diffuse large B-cell lymphoma. It's for patients who aren't candidates for stem cell transplant or CAR-T therapy. The trial will fi…

This study is testing two different drug combinations for people with multiple myeloma, a type of blood cancer, that has stopped responding to many standard treatments. It aims to see if these new combinations can help control the cancer and are safe for patients. The trial is fo…

This study is testing whether a drug called selinexor can help keep advanced endometrial cancer from returning or worsening after patients have successfully responded to initial chemotherapy. About 276 patients whose cancer has a specific genetic profile (p53 wild-type) will rece…

This study is testing an oral medication called selinexor for adults with a fast-growing type of lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and control the disease in patients who have no other pr…

This study is testing 12 different combinations of an experimental drug called selinexor with other approved myeloma medications. It aims to find safe and effective treatment options for adults whose multiple myeloma has returned after prior therapy or who are newly diagnosed. Th…

This program provides the investigational drug selinexor to patients with certain cancers who have run out of standard treatment options and don't qualify for ongoing clinical trials. It allows doctors to request the drug for eligible patients before it receives full regulatory a…

This study is testing whether the drug selinexor can reduce spleen size and ease symptoms in people with myelofibrosis, a type of bone marrow cancer, who also have low platelet counts and have not yet taken common JAK inhibitor drugs. About 58 participants will take selinexor alo…